Mirati Therapeutics (NASDAQ:MRTX) and Clearside Biomedical (NASDAQ:CLSD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.
Valuation & Earnings
Get Mirati Therapeutics alerts:This table compares Mirati Therapeutics and Clearside Biomedical’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mirati Therapeutics | N/A | N/A | -$70.42 million | ($2.78) | -25.82 |
| Clearside Biomedical | $340,000.00 | 136.57 | -$58.97 million | ($2.33) | -0.62 |
Clearside Biomedical has higher revenue and earnings than Mirati Therapeutics. Mirati Therapeutics is trading at a lower price-to-earnings ratio than Clearside Biomedical, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Mirati Therapeutics and Clearside Biomedical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Mirati Therapeutics | N/A | -46.80% | -42.71% |
| Clearside Biomedical | N/A | -142.46% | -102.76% |
Risk & Volatility
Mirati Therapeutics has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of -1.3, indicating that its stock price is 230% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for Mirati Therapeutics and Clearside Biomedical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mirati Therapeutics | 0 | 1 | 9 | 0 | 2.90 |
| Clearside Biomedical | 1 | 2 | 5 | 0 | 2.50 |
Mirati Therapeutics presently has a consensus price target of $60.00, suggesting a potential downside of 16.41%. Clearside Biomedical has a consensus price target of $12.71, suggesting a potential upside of 776.85%. Given Clearside Biomedical’s higher possible upside, analysts clearly believe Clearside Biomedical is more favorable than Mirati Therapeutics.
Institutional and Insider Ownership
97.9% of Mirati Therapeutics shares are owned by institutional investors. Comparatively, 57.6% of Clearside Biomedical shares are owned by institutional investors. 4.9% of Mirati Therapeutics shares are owned by company insiders. Comparatively, 15.4% of Clearside Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; Array BioPharma, Inc.; and Bristol-Myers Squibb Company to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
No comments:
Post a Comment